IMU Biosciences

Private

LondonHealthcare & Life Scienceshttps://imubiosciences.com/

Last Round

Series A

Jun 2, 2026

Total Funding Raised

$166M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

IMU Biosciences is a biotechnology company that provides an immune discovery platform using systems-level profiling and AI to advance precision medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

immune profilingsystems immunologybiomarker discoverymass cytometrypatient stratificationdrug discoveryprecision medicinemulti-omicsclinical trial supportimmune phenotypingAI drug discoverycomputational biologybiotech analyticsdigital twinimmune mapping

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IMU Biosciences Comps

Public and private peers based on sector, stage, and business model.

IMU Biosciences comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

IMU Biosciences Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jun 2, 2026
Series A	Jun 2, 2026
Series A	Jan 24, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

Mario Cantero

Co-Founder COO

Founding Team

Tom Hayday

Co-founder Chief Research Officer (CRO)

Founding Team

John Baker

Chief Executive Officer

Executive Team

IMU Biosciences Investors

Notable investors and investment history

IMU Biosciences investors
Investor	Rounds
LifeX Ventures	Series A, Seed
LifeX Ventures	Series A
British Business Bank	Series A
Meltwind Advisory	Series A
IQ Capital	Series A
Kfund	Series A
Molten Ventures	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 2, 2026
$38M round led by IQ Capital and Molten Ventures.
Jun 2, 2026
$53M round led by IQ Capital and Molten Ventures.

View all signals

IMU Biosciences Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

IMU Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IMU Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon

Employee Range77

Year Founded2019

Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.